Article - 18/12/2012 Gene therapy medicinal products: the first gene therapy product has been approved – where does the future lie? Is gene therapy close to broad clinical application? Following negative headlines at the end of the 1990s gene therapy had almost disappeared from the public radar to become an issue almost exclusively dealt with by research laboratories. Gene therapy has now reappeared in the public domain since the European Medicines Agency EMA gave the Dutch biotech company uniQure the go-ahead for the application of somatic gene therapy for the treatment of a…https:////www.gesundheitsindustrie-bw.de/en/article/news/gene-therapy-medicinal-products-the-first-gene-therapy-product-has-been-approved-where-does-the-futu
Press release - 17/12/2012 Curetis AG initiates clinical trial in the U.S. towards FDA clearance Curetis AG announced the start of a clinical trial of its Unyvero™ System and the corresponding LRT (lower respiratory tract) application in the U.S. The company expects enrollment completion within the next 12-15 months, followed by a 510(k) submission to the FDA in 2014. The prospective, multicenter trial will include samples collected from more than 2,000 hospitalized patients suspected to have a lower respiratory tract infection and several…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-initiates-clinical-trial-in-the-u-s-towards-fda-clearance
Article - 03/12/2012 Targeted therapeutic approaches that revolutionise melanoma treatment Melanoma is difficult to treat once it has spread from the skin to other parts of the body. Classical chemotherapy is often ineffective and the majority of patients die within a few months after diagnosis. However, the biggest breakthrough in around 30 years has now been achieved with the development of kinase inhibitors that directly interfere with the cancer cells’ molecular signalling pathways. Clinical research into the application of kinase…https:////www.gesundheitsindustrie-bw.de/en/article/news/targeted-therapeutic-approaches-that-revolutionise-melanoma-treatment
Press release - 12/11/2012 immatics appoints Peter Chambré as Chairman immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced the appointment of Peter Chambré as Chairman of the Board with immediate effect. Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry. He will replace Thomas Widmann, who has…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-peter-chambr-as-chairman
Press release - 09/11/2012 Apogenix’s Apocept™ for glioblastoma multiforme named one of “Top 10 Projects to Watch” Apogenix a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases announced that its lead product Apocept APG101 has been selected by Elsevier Business Intelligence and Windhover Conferences as one of oncologys Top 10 Projects To Watch.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-s-apocept-for-glioblastoma-multiforme-named-one-of-top-10-projects-to-watch
Press release - 30/10/2012 DKFZ and Genetic Immunity Sign Collaboration Agreement to Develop HPV Therapeutic Vaccine Genetic Immunity, Budapest, a leader in immunotherapy technology product development, and DKFZ (German Cancer Research Center, Heidelberg, Germany) signed a collaborative agreement to develop a DNA-based vaccine for the treatment of Human Papilloma Virus (HPV) infection that causes cervical cancer and other cancers of the anus, penis, vulva, vagina, and oropharynx. Present HPV vaccines (Cervarix, Gardasil) have no therapeutic effect on…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-and-genetic-immunity-sign-collaboration-agreement-to-develop-hpv-therapeutic-vaccine
Article - 22/10/2012 syneed imaging: precise visualisation of functional tissue properties Functional medical imaging modalities are of great significance in modern medical diagnostics. Existing ways of diagnosing diseases are now being expanded with the arrival of the innovative parameter imaging method. syneed imaging uses proprietary highly sensitive software for the analysis of dynamic image data. This software complements standard methods such as computed tomography and magnetic resonance imaging and increases the significance of…https:////www.gesundheitsindustrie-bw.de/en/article/news/syneed-imaging-precise-visualisation-of-functional-tissue-properties
Article - 10/09/2012 Jan Wehkamp to investigate the causes of chronic inflammatory bowel diseases It takes a great deal of courage to question a common scientific doctrine especially for scientists at the very beginning of their careers. But around ten years ago Dr. Jan Wehkamp did not shy away from doing just that and as a result he and his scientific partner Professor Dr. Eduard Stange came up with a new explanation for the pathogenesis of chronic inflammatory bowel diseases.https:////www.gesundheitsindustrie-bw.de/en/article/news/jan-wehkamp-to-investigate-the-causes-of-chronic-inflammatory-bowel-diseases
Press release - 08/08/2012 Apogenix: APG101 Exceeds Expectations with Controlled Phase II Clinical Trial The biopharmaceutical company Apogenix GmbH announced today that the phase II clinical proof of concept trial with APG101 as treatment of recurrent glioblastoma has met and exceeded expectations in the final analysis of the data. In this randomized controlled clinical study the patients were treated either with a combination of APG101 plus radiotherapy (APG101+RT group) or radiotherapy alone (RT group). The primary objective of the trial was to…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-apg101-exceeds-expectations-with-controlled-phase-ii-clinical-trial
Press release - 07/08/2012 immatics announces publication of IMA901 cancer vaccine data in Nature Medicine immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine. The paper highlights that renal cell carcinoma patients experience longer survival times when their immune system produces an immune response to…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-announces-publication-of-ima901-cancer-vaccine-data-in-nature-medicine
Press release - 24/07/2012 Tailor-made viruses for enhanced cancer therapy Parvoviruses specifically kill cancer cells and are already in the clinical trial stage for treating malignant brain tumors. However, as they can also infect normal cells - without doing any harm to them - a large portion of viruses is lost during therapy. Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now modified parvoviruses in such a way that they initially lose their ability to infect cells. In…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/tailor-made-viruses-for-enhanced-cancer-therapy
Article - 16/04/2012 Pharma 2.0: towards paperless production Before electronic solutions existed lorries were needed to ship new drug applications which often comprised 500000 or so pages. Thanks to IT this is no longer necessary. IT-based procedures and solutions are playing an increasing role in all areas of the pharmaceutical industry. Markus Roemer CEO of Ravensburg-based comes compliance services supports companies in implementing legal guidelines in this area. In the following interview Roemer talks…https:////www.gesundheitsindustrie-bw.de/en/article/news/pharma-2-0-towards-paperless-production
Article - 20/02/2012 Klaus Pfizenmaier: bridging the fields between immunology and biomedicine Prof. Dr. Klaus Pfizenmaier has been focusing on cytokines, and in particular on the tumour necrosis factor TNF, for the last 25 years. Pfizenmaier and his team of researchers at the Institute of Cell Biology and Immunology at the University of Stuttgart have unravelled numerous facets of TNF, which is a key and versatile signalling molecule. These discoveries have led to the development of groundbreaking therapy concepts and drug candidates for…https:////www.gesundheitsindustrie-bw.de/en/article/news/klaus-pfizenmaier-bridging-the-fields-between-immunology-and-biomedicine
Press release - 02/02/2012 Colorectal cancer: Phase II results with cancer vaccine IMA910 are positive immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced positive results from its Phase II clinical trial with IMA910 in patients with advanced colorectal cell carcinoma (CRC) which were presented at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in San Francisco. IMA910 comprises 13 tumor-associated…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/colorectal-cancer-phase-ii-results-with-cancer-vaccine-ima910-are-positive
Article - 16/01/2012 Manfred Jung: drug discovery and the epigenetic code Prof. Dr. Manfred Jungs team at the University of Freiburg are chemical epigeneticists whose research involves the development of methods that enable them to identify and optimise new therapeutic drugs which are able to alter the epigenetic code of cancer and other cell types. The team use a perfidious worm for their research.https:////www.gesundheitsindustrie-bw.de/en/article/news/manfred-jung-drug-discovery-and-the-epigenetic-code
Press release - 10/01/2012 Apogenix receives additional 2.3 million Euros BMBF grant as partner of the biotech cluster Rhine-Neckar The biopharmaceutical company Apogenix GmbH today announced that it has received an additional € 2.3 million BMBF grant (German Federal Ministry of Education and Research) for the further advancement of its lead substance APG101. Apogenix will use the proceeds to develop APG101 for the treatment of myelodysplastic syndromes (MDS). More specifically, the grant will be used for the production of clinical material and for the development of a…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-receives-additional-2-3-million-euros-bmbf-grant-as-partner-of-the-biotech-cluster-rhine-ne
Article - 09/01/2012 Nutritional medicine: Can certain foods help treat cancer? Researchers at the Centre for Nutritional Medicine (ZEM), a joint institution of the Universities of Hohenheim and Tübingen, are investigating whether and to what extent certain food components can support the treatment of cancer and are hoping to derive scientifically founded dietary recommendations from their findings.https:////www.gesundheitsindustrie-bw.de/en/article/news/nutritional-medicine-can-certain-foods-help-treat-cancer
Press release - 09/01/2012 Apogenix Raises 7.5 Million Euros to Further Advance APG101 to Treat Glioblastoma and other Tumors The biopharmaceutical company Apogenix GmbH today announced the successful completion of a € 7.5 million financing round led by dievini Hopp BioTech holding GmbH & Co. KG (dievini). Other investors include the German Cancer Research Center (DKFZ), the founders and the executive management team of Apogenix. These funds will enable Apogenix to further advance the phase II clinical trial of APG101 to treat Glioblastoma Multiforme (GBM) and other…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-raises-7-5-million-euros-to-further-advance-apg101-to-treat-glioblastoma-and-other-tumors
Article - 09/01/2012 Biomarkers to combat lung cancer A biomarker-driven personalised therapeutic approach to lung cancer is possible – this is the conclusion reached by the BATTLE trial. The preliminary results of the trial were summarised by scientists from the Thoraxklinik at Heidelberg University Hospital in the May 2011 issue of “Clinical Investigation”.https:////www.gesundheitsindustrie-bw.de/en/article/news/biomarkers-to-combat-lung-cancer
Article - 12/12/2011 Rheumatoid arthritis biomarkers A plethora of biomarkers is available for the early diagnosis of rheumatoid arthritis and associated tissue damage and disorders. In addition, new biomarkers that improve the diagnosis and treatment of patients suffering from this common destructive autoimmune disease are constantly being discovered.https:////www.gesundheitsindustrie-bw.de/en/article/news/rheumatoid-arthritis-biomarkers
Article - 14/11/2011 BioTeSys GmbH - The basics of substance testing Esslingen-based BioTeSys GmbH is contracted by its clients to determine the bioactive potential of substances and substance mixtures of foods and dietary supplements. Substances are tested whether or not they have a positive effect on human health using a range of chemical analyses, cell-based tests and clinical trials. https:////www.gesundheitsindustrie-bw.de/en/article/news/biotesys-gmbh-the-basics-of-substance-testing
Press release - 02/11/2011 Using Viruses to Fight Brain Tumors Parvoviruses can enter and kill cancer cells, but they do not cause disease in humans. Since 1992, scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have been studying these viruses with the aim of developing a viral therapy against dangerous brain tumors that are almost impossible to treat. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/using-viruses-to-fight-brain-tumors
Article - 17/10/2011 Papillomaviruses as cancer-causing agents and how they can be fought off Studies presented at the recent International Papillomavirus Conference in Berlin demonstrate that vaccination can prevent infection with the types of HPV that cause the majority of cervical cancers. New improved vaccines to prevent HPV infections as well as therapeutic vaccines that are effective in people that are already infected are currently being developed. In addition, research has shown that other cancers can also be caused by infective…https:////www.gesundheitsindustrie-bw.de/en/article/news/papillomaviruses-as-cancer-causing-agents-and-how-they-can-be-fought-off
Dossier - 05/10/2011 Biosimilars: follow-on biologics of innovator biopharmaceutical products As blockbuster biopharmaceuticals go off patent, biosimilars are increasingly competing with them for a market share. However, the production of biosimilars is rather complex and costly. The approval of biosimilars is also subject to many hurdles. Their introduction to the very expensive biopharmaceuticals market is often associated with marginal price reductions.https:////www.gesundheitsindustrie-bw.de/en/article/dossier/biosimilars-follow-on-biologics-of-innovator-biopharmaceutical-products
Article - 12/09/2011 TransLimm brings new immunotherapies to patients more rapidly With the establishment of the Center for Translational Immunology TransLimm the University of Tübingen has initiated a network whose objective is to quickly and effectively transfer innovative therapies into clinical application. Patients suffering from acute leukaemia might soon benefit from therapies involving antibodies optimized by recombinant antibody technology. https:////www.gesundheitsindustrie-bw.de/en/article/news/translimm-brings-new-immunotherapies-to-patients-more-rapidly